Global Prevalence of Insufficient Activity 27.5 Percent
Levels of insufficient physical activity stable between 2001, 2016; increase seen in high-income countries
No Clear Benefit for Rivaroxaban After Hospital Discharge
Incidence of major bleeding low with rivaroxaban, but clot risk not lower
Compliance With Requirement to Report Results on EUCTR Is Poor
Half of trials on European Union Clinical Trials Register are non-compliant with requirements
Drug Prices Increase More Than Expected After Shortages
Expected price increase 20 percent for all drugs after shortage versus 9 percent in absence of shortage
Scribes Improve Physician Workflow, Patient Interaction
Scribes lower EHR documentation burden for doctors and increase time spent interacting with patients
Tafamidis Treats Transthyretin Amyloid Cardiomyopathy
Reduces all-cause mortality, cardiovascular-related hospitalizations compared with placebo
Tips for Advising Patients Living in Highly Polluted Settings
Guidance focuses on Americans posted in overseas settings with high ambient levels of air pollution
Ranolazine Doesn’t Cut VT, VF, Death in High-Risk ICD Patients
No significant reduction in VT or VF or death risk for patients with implantable cardioverter-defibrillators
Drug Prices Seem Not to Be Influenced by Their Value
Incremental cost-effectiveness ratio of 30 heart medications varied from cost-saving to costly
Model Estimates Mortality in Patients Waiting for Hearts
Neurologic events, new requirement for dialysis, respiratory complications yield updated estimates
